title: Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon.
abstract: With modern risk-adapted therapy, over 80% of children with acute lymphoblastic leukemia (ALL) in high-income countries (HICs) are cured. In countries with limited resources, however, therapy results for pediatric ALL are still not encouraging. We describe our experience in treating children with ALL using a risk-adapted protocol at a tertiary referral center in Lebanon. From May 2002 to August 2009, 111 consecutive patients 1-21 years of age with newly diagnosed ALL received the CCCL ALL protocol which was based on the St. Jude Children's Research Hospital Total XV Study. The median age at diagnosis was 5 years 5 months. The male to female ratio was 1.5. Forty-six patients received the intermediate-/high-risk arm and 65 received the low-risk arm. Only one patient (0.9%) died during induction therapy. Relapse occurred in 8 (7.2%) patients. Eight (7.2%) patients died, 4 of whom were in remission. The median follow-up of the patients was 38 months. The 5-year overall survival and event-free survival were and 88.5% (95% CI: 77.1-94.4) and 78.7% (95% CI: 69.8-88.4), respectively. Our results are comparable to those in HICs in spite of the limited resources and the relatively low socioeconomic status of the Lebanese population. Children treated on this protocol experienced significant toxicity necessitating expert supportive care, but benefited from improved cure rates and prolonged survival.
authors.affiliation: Department of Pediatrics and Adolescent Medicine, Children's Cancer Center of Lebanon, American University of Beirut Medical Center, Beirut, Lebanon. sm03@aub.edu.lb
authors.forename: Samar
authors.initials: S
authors.lastname: Muwakkit
authors.forename: Carol
authors.initials: C
authors.lastname: Al-Aridi
authors.forename: Ahmad
authors.initials: A
authors.lastname: Samra
authors.forename: Raya
authors.initials: R
authors.lastname: Saab
authors.forename: Rami A
authors.initials: RA
authors.lastname: Mahfouz
authors.forename: Chantal
authors.initials: C
authors.lastname: Farra
authors.forename: Sima
authors.initials: S
authors.lastname: Jeha
authors.forename: Miguel R
authors.initials: MR
authors.lastname: Abboud
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002173:Cancer Care Facilities; D002648:Child; D002675:Child, Preschool; D003906:Developing Countries; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007861:Lebanon; D008297:Male; D009894:Opportunistic Infections / Q000150:complications; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D011379:Prognosis; D012074:Remission Induction; D055502:Secondary Prevention; D016019:Survival Analysis; D055815:Young Adult